Alzheimer's Disease Flashcards

(78 cards)

1
Q

What is dementia?

A

Dementia is a broad term describing various conditions characterized by cognitive decline and memory impairment. It is a symptom of Alzheimer’s Disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the most common type of dementia?

A

Alzheimer’s Disease (AD) is the most common type of dementia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are some other types of dementia?

A

Other types of dementia mentioned include Dementia with Lewy Bodies (DLB), Vascular Dementia, and Frontotemporal Dementia (FTD).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the two main pathological hallmarks in the brain that mark Alzheimer’s Disease (AD)?

A

AD is marked by the buildup of Amyloid Plaques and Tau Tangles (Neurofibrillary Tangles) in the brain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are Amyloid Plaques and where are they found in the brain?

A

Amyloid Plaques are extracellular deposits found between neurons. They are aggregates of amyloid beta (Aβ) peptides.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are Tau Tangles and where are they found? What is the normal function of tau protein?

A

Tau Tangles are intracellular abnormal protein deposits found within neurons. Tau is a microtubule-associated protein found in the axon that normally transports proteins and mRNA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Where do the amyloid plaques and tau tangles typically first appear in the brain in AD?

A

These abnormalities typically appear first in the hippocampus and associated cortical regions, which are crucial for memory and learning.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How does the pathology spread as Alzheimer’s Disease progresses?

A

As the disease progresses, these pathological changes spread to other parts of the cortex and the brain, leading to widespread cognitive decline.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How do the brains of individuals with AD typically look different compared to normal brains?

A

Normal brains show tight-packed gyri, while AD brains show tissue loss, large ventricles, and significant degeneration, particularly in the hippocampus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is notable about the time course of Alzheimer’s Disease development?

A

The development of AD involves a long time course of events, making treatment difficult.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How early does amyloid plaque buildup begin before an AD diagnosis?

A

Amyloid plaque buildup begins decades before AD is diagnosed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the initial effects of amyloid plaque buildup, and do they typically lead to an early diagnosis?

A

Initially, amyloid buildup may cause synaptic dysfunction and localized effects on synapses, possibly leading to subtle symptoms like aggression or vagueness. However, these are typically not alarming cognitive deficits that result in the need to get a diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What happens with soluble amyloid beta (Aβ) early in AD development?

A

A significant accumulation of soluble amyloid beta (Aβ) occurs initially.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Can triggers increase soluble Aβ, and what happens if the insult is too large or repeated?

A

Some triggers like physical trauma, tiny strokes, or high fever might temporarily increase soluble Aβ as a protective mechanism. However, if the insult is too big, repeated, or due to genetic makeup, the Aβ does not decrease, leading to decades of plaque buildup.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What does continued Aβ exposure trigger?

A

Continued Aβ exposure triggers a feedforward mechanism, increasing plaque accumulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

When is tau tangle buildup typically seen in the time course of AD?

A

Tau tangle buildup is seen later than amyloid plaque buildup.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is closely linked to cognitive impairment and AD diagnosis in terms of pathology?

A

Substantial tau tangle accumulation is closely linked to cognitive impairment and causes loss of synapses, cell death, and loss of brain tissue, leading to AD diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What kind of brain structure changes can occur before an AD diagnosis?

A

Brain structure changes, such as up to 15% loss of the hippocampus, can occur before AD is diagnosed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How might patients initially cope with memory symptoms in the preclinical phase of AD?

A

Patients may initially learn to compensate for memory symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Are amyloid plaques sufficient by themselves for a diagnosable AD?

A

Plaques by themselves are not sufficient for a diagnosable AD; tau tangles are also needed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are some typical early symptoms of AD?

A

Typical early symptoms may include regularly forgetting recent events, names, and faces, becoming increasingly repetitive (like repeating questions), uncertainty about the date or time, regularly misplacing items, getting lost (especially in unfamiliar places), problems finding the right words, and changes in mood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What happens to symptoms as AD develops?

A

As the disease develops, the ability to think and make decisions worsens. Communication and language become more difficult, and there is difficulty recognizing objects or familiar faces.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How does AD affect daily activities and motor functions as it progresses?

A

As AD develops, there is difficulty using household appliances or locating objects, changes in sleep patterns, and problems with walking, balance, and swallowing. Plaques reach all parts of the brain, affecting motor function. There is also an increased need for help with daily activities like dressing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What kind of psychosis symptoms can occur in AD?

A

Psychosis symptoms can also occur, including delusions and hallucinations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What are delusions in the context of AD?
Delusions are fixed, false beliefs that cannot be corrected by logic and are not consistent with the patient's culture and education.
26
What are some common delusions experienced by people with AD?
Common delusions include beliefs that people are stealing things, the house is not one's home, a spouse is an imposter, or infidelity, as well as suspiciousness/paranoia.
27
What is a major difficulty in treating Alzheimer's Disease?
A major difficulty is that drugs given after significant plaque and tangle buildup are often less effective.
28
When would ideally treatment occur for AD?
Ideally, treatment would occur before diagnosis, during the long preclinical phase of plaque accumulation.
29
If brain tissue has already been lost, will getting rid of tau tangles solve the disease?
Getting rid of tau tangles after brain tissue has already been lost will not solve the disease.
30
What is considered an ideal prevention strategy for AD?
Preventing amyloid buildup would be ideal.
31
How might early detection using plasma biomarkers help in treating AD?
Early detection using plasma biomarkers might help target the window when preventing amyloid buildup is possible.
32
What is a limitation of existing drugs for AD?
Existing drugs primarily treat symptoms for some time but do not alter the fundamental disease time course. They do not change the disease time course itself.
33
What happens if symptomatic AD medication is removed?
Removing the medication would revert the person to the state they would have been in without treatment.
34
What are some examples of symptomatic treatments for AD?
Symptomatic treatments may include antipsychotics or BDZ for sleep, agitation, and psychosis.
35
Describe the Non-amyloidogenic pathway of APP processing.
The Non-amyloidogenic pathway is protective. α-secretase cleaves APP within the Aβ region, preventing Aβ formation and producing soluble-APP α (sAPPα), which supports brain health.
36
Describe the Amyloidogenic pathway of APP processing.
The Amyloidogenic pathway generates toxic Aβ peptides. It begins with cleavage by beta-secretase (BACE1), followed by gamma-secretase, releasing Aβ peptides, particularly the aggregation-prone Aβ42. These peptides can accumulate into oligomers and plaques.
37
Which enzyme involved in APP processing is elevated in early AD?
Beta-secretase (BACE1) is elevated in early AD.
38
Why are animal models, particularly mice, essential in AD research?
Animal models, particularly mice, are essential for testing potential treatments and understanding disease mechanisms.
39
What changes resembling human AD are necessary to induce in model organisms for research?
It is necessary to induce amyloid beta accumulation, plaque deposition with microglia involvement, local synapse loss, delayed tau tangle formation, cell death, and cognitive impairment in model organisms.
40
What are some different types of mouse models used in AD research?
Different mouse models exist, including Amyloid Mice, Tau Transgenic Mice, and Tau Knock-in Mice.
41
What kind of genetic mutations are often carried by Amyloid Mice models?
Amyloid Mice carry familial AD mutations in genes like APP and PSEN1/PSEN2. These often involve transgenic overexpression or knock-in mutations.
42
What features do Amyloid Mice models typically show?
They show plaque buildup, microglia involvement, and subtle behavioural changes. However, they often show little to no tau tangles or neurodegeneration.
43
What is a major challenge with current AD animal models?
A major challenge is that current models effectively capture the amyloid part (early) and the tau part (late) but struggle to link them in a way that reflects human AD progression.
44
What are some examples of APP mutations used in knock-in mouse models and what are their effects?
Examples include NL (Swedish) which increases Aβ production, F (Iberian) which increases the proportion of Aβ42:Aβ40 promoting deposition, and G (Arctic) which causes a conformational change increasing Aβ oligomerization/fibrillization.
45
How does plaque development compare between AppNL-F and AppNL-G-F knock-in mice as they age?
Plaques develop with age in both models. In AppNL-F mice, sparse plaques appear around 9 months and are reliably detected by 14 months, spreading by 18-24 months. In AppNL-G-F mice, a few small plaques are seen at 2 months, and plaque load is heavier than 24-month-old NL-F mice by 4 months, with substantial load by 9 months.
46
Was a significant effect of sex observed on pathology score in the AppNL-F and AppNL-G-F mouse models?
There was no significant effect of sex on pathology score at any age in either model.
47
How does soluble beta (Aβ) affect synaptic function in these mouse models?
Soluble beta (Aβ) may increase release probability at synapses even before plaque formation.
48
What is the paired-pulse ratio (PPR) and what does it indicate about synaptic function?
The paired-pulse ratio is a measure of release probability at a synapse. It is calculated by dividing the amplitude of the second response by the first. High probability synapses tend to have a PPR of less than 1, while low probability synapses tend to have a PPR of more than 1.
49
How does release probability change in NL-F and NL-G-F mice?
In NL-F mice, release probability increases before plaques. In NL-G-F mice, release probability increases before plaques but decreases as intense plaque formation occurs, possibly because soluble beta is consolidated into plaques. The effect returns with very heavy plaque load.
50
What does an increased release probability mean for synaptic response?
Increased release probability means a decreased failure rate of synaptic response.
51
Which mouse model, AppNL-F or AppNL-G-F, is considered more similar to sporadic human AD in terms of time course?
The AppNL-F model is considered more similar to sporadic human AD in terms of time course and late-onset pathology.
52
Why do many researchers prefer the AppNL-G-F model despite AppNL-F potentially better reflecting sporadic AD time course?
Many researchers prefer NL-G-F due to its higher sensitivity and heavily expressed pathology, making it easier to measure and study.
53
What are microglia and what is their role in the brain, particularly in relation to plaques?
Microglia are immune cells in the brain that detect and respond to damage. They can cluster around plaques and facilitate the clearance of Aβ and damaged cells.
54
Can microglia help prevent widespread axonal damage caused by plaques?
Contact between axons and toxic amyloid plaques can induce damage mediated by tau phosphorylation. Microglia can remove Aβ-damaged synapses, potentially preventing widespread axonal damage.
55
What happens to microglia density with increasing plaque load?
Microglia density increases with plaque load. There is a very high correlation between plaque load and microglial involvement.
56
Do microglia react to plaques, tau, or both?
Microglia react to plaques, not tau
57
What is TREM2 and what is its function?
TREM2 is a receptor expressed on microglia. It senses damage and promotes microglial clustering around plaques.
58
What effect do mutations in TREM2, such as R47H, have in humans?
In humans, mutations in TREM2, such as R47H, impair microglial function and significantly increase AD risk (up to 3x in homozygous carriers). These tend to be loss-of-function mutations.
59
How does TREM2 expression often differ between mouse models and humans?
Interestingly, in mouse models, TREM2 is often massively overexpressed.
60
What is a possible protective effect of TREM2 overexpression in mice?
This overexpression and associated genes might be protective in mice by effectively removing damaged synapses and preventing tau tangles.
61
What pathway is involved when TREM2 expression increases in response to a damaged synapse?
TREM2 increases expression in response to an 'eat me' signal on a damaged synapse. This pathway involves the complement pathway and phagocytosis of damaged synapses via genes like Pleckstrin. Lysosomal factors are also involved in waste removal.
62
What are APPTrem2 models and what is their purpose?
APPTrem2 models (e.g., AppNLF/NLFxTrem2R47H/R47H) are new mouse models that integrate the AppNLF knock-in with a human TREM2 R47H risk mutation. They allow researchers to study the interaction between Aβ pathology and microglial dysfunction driven by genetic risk factors.
63
What findings have been made in NLFTrem2R47H mice regarding microglia?
In NLFTrem2R47H mice (which have impaired Trem2 function), microglia show reduced clustering around plaques. Trem2 expression in microglia, even those touching plaques, is significantly reduced compared to NL-F mice.
64
How do genes associated with the TREM2 pathway respond in NLFTrem2R47H mice?
Genes associated with the TREM2 pathway (like CD68) also show reduced expression in response to plaques in the presence of the Trem2 mutation. This reduced response may help mimic human-like microglial dysfunction.
65
What are NLFhTau mice and why were they developed?
NLFhTau mice (AppNLF/NLFx human Tau) are new mouse models developed to address the difference between mouse and human tau. Mice normally have only 4R tau isoforms, while adult humans have a mix of 3R and 4R tau, and AD is a mixed 3R:4R tauopathy.
66
What is the tau isoform ratio like in NLFhTau mice?
These mice are heterozygous for human and mouse tau, providing a 3R:4R ratio similar to human AD.
67
What research technique is used to study fast synaptic transmission in brain slices?
Electrophysiology is used to study fast synaptic transmission in brain slices.
68
What are some techniques used in electrophysiology for AD research?
Techniques include Patch clamp (recording from single neurons) and Field recording (recording from multiple neurons).
69
What can be measured using electrophysiology techniques in brain slices?
Electrophysiology can be used to measure synaptic currents and release probability.
70
What is spatial cell-enriched transcriptomics?
Spatial cell-enriched transcriptomics is an emerging technology allowing researchers to examine gene expression in specific cell types (e.g., microglia) within distinct brain regions.
71
How does spatial cell-enriched transcriptomics work to identify cell location?
This technology uses "bar codes" to label cells based on location.
72
What kind of comparisons are possible using spatial cell-enriched transcriptomics?
It allows comparison of gene expression in cells near or away from plaques (e.g., microglia touching plaques vs. >30 microns away). It also enables comparison of different brain regions within the same animal.
73
What kind of genes and risk factors have GWAS highlighted as important in AD?
GWAS highlights the importance of microglia genes like TREM2 and risk factors like APOE4.
74
What is an advantage of spatial cell-enriched transcriptomics when studying human tissue?
This technique is especially useful when studying human tissue post-mortem, where treatment can vary, because it allows comparison of different brain regions within the same individual.
75
What are GWAS and what is their purpose in AD research?
GWAS (Genome-Wide Association Studies) compare genetic data from individuals with and without AD to identify risk variants.
76
Do the genes identified by GWAS directly cause AD?
Some identified genes are risk factors that accelerate disease (e.g., TREM2 R47H, APOE4), not direct causes.
77
What has RNA sequencing data suggested about mitochondrial damage in a mouse model of AD?
RNA sequencing data suggests almost complete loss of mitochondrial ATPase in AppNLFhTau mice at 18-24 months.
78
How strong a risk factor is APOE4 for AD?
APOE4 is a strong risk factor, especially in homozygous individuals, where it is almost causative.